{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T10:31:35Z","timestamp":1786444295312,"version":"build-2736575974"},"reference-count":99,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2026.15775","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:42:22Z","timestamp":1784612542000},"page":"1-17","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant therapy for stage II\u2011III triple\u2011negative breast cancer: Current evidence, clinical boundaries and emerging strategies (Review)"],"prefix":"10.3892","volume":"32","author":[{"given":"Bingchen","family":"Li","sequence":"first","affiliation":[{"name":"Department of Clinical Medicine, Jining Medical University, Jining, Shandong 272000, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchen","family":"Tian","sequence":"additional","affiliation":[{"name":"Clinical Medical Laboratory Center, Jining No. 1 People's Hospital, Jining, Shandong 272000, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-Qing","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Jining No. 1 People's Hospital, Jining, Shandong 272000, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Oncology, Jining No. 1 People's Hospital, Jining, Shandong 272000, P.R.\u00a0China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"key20260811124601_b1-ol-32-3-15775","first-page":"e70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"CA Cancer J Clin"},{"key":"key20260811124601_b2-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-negative breast cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"N Engl J Med"},{"key":"key20260811124601_b3-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev-pathol-042420-093238","article-title":"Pathogenesis of triple-negative breast cancer","volume":"17","author":"Derakhshan","year":"2022","journal-title":"Annu Rev Pathol"},{"key":"key20260811124601_b4-ol-32-3-15775","article-title":"AJCC Cancer Staging Manual","author":"Amin","year":"2017","edition":"8th edition"},{"key":"key20260811124601_b5-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.20.03399","article-title":"Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline","volume":"39","author":"Korde","year":"2021","journal-title":"J Clin Oncol"},{"key":"key20260811124601_b6-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N Engl J Med"},{"key":"key20260811124601_b7-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMoa2112651","article-title":"Event-free survival with pembrolizumab in early triple-negative breast cancer","volume":"386","author":"Schmid","year":"2022","journal-title":"N Engl J Med"},{"key":"key20260811124601_b8-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"5249","DOI":"10.1158\/1078-0432.CCR-22-1110","article-title":"FDA approval summary: Pembrolizumab for neoadjuvant and adjuvant treatment of patients with high-risk early-stage triple negative breast cancer","volume":"28","author":"Shah","year":"2022","journal-title":"Clin Cancer Res"},{"key":"key20260811124601_b9-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1200\/JCO.22.00503","article-title":"Endocrine Therapy, Targeted Therapy for Breast Cancer Guideline Expert Panel: Use of immune checkpoint inhibitor pembrolizumab in the treatment of high-risk, early-stage triple-negative breast cancer: ASCO guideline rapid recommendation update","volume":"40","author":"Korde","year":"2022","journal-title":"J Clin Oncol"},{"key":"key20260811124601_b10-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"18","DOI":"10.21037\/tbcr-24-31","article-title":"Chinese Society of Clinical Oncology (CSCO) Breast Cancer guidelines 2024","volume":"5","author":"Li","year":"2024","journal-title":"Transl Breast Cancer Res"},{"key":"key20260811124601_b11-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/j.annonc.2023.08.017","article-title":"Understanding breast cancer complexity to improve patient outcomes: The St. Gallen International consensus conference for the primary therapy of individuals with early breast cancer 2023","volume":"34","author":"Curigliano","year":"2023","journal-title":"Ann Oncol"},{"key":"key20260811124601_b12-ol-32-3-15775","first-page":"1","article-title":"Integrating immunotherapy into the treatment landscape for patients with triple-negative breast cancer","volume":"42","author":"Dixon-Douglas","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"key20260811124601_b13-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1186\/s12885-024-12222-9","article-title":"Long-term survival after neoadjuvant therapy for triple-negative breast cancer under different treatment regimens: A systematic review and network meta-analysis","volume":"24","author":"Liu","year":"2024","journal-title":"BMC Cancer"},{"key":"key20260811124601_b14-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41523-022-00386-1","article-title":"Immunotherapy for early triple negative breast cancer: Research agenda for the next decade","volume":"8","author":"Tarantino","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"key20260811124601_b15-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/bcr2852","article-title":"Stratifying triple-negative breast cancer: Which definition(s) to use?","volume":"13","author":"Adamo","year":"2011","journal-title":"Breast Cancer Res"},{"key":"key20260811124601_b16-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.annonc.2024.02.002","article-title":"Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: Exploratory analysis from KEYNOTE-522","volume":"35","author":"Pusztai","year":"2024","journal-title":"Ann Oncol"},{"key":"key20260811124601_b17-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11912-023-01487-1","article-title":"Immunotherapy for early-stage triple negative breast cancer: Is earlier better?","volume":"26","author":"Song","year":"2024","journal-title":"Curr Oncol Rep"},{"key":"key20260811124601_b18-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13058-022-01552-w","article-title":"Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial","volume":"24","author":"Kolberg-Liedtke","year":"2022","journal-title":"Breast Cancer Res"},{"key":"key20260811124601_b19-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/j.annonc.2021.03.016","article-title":"Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): Analysis of the GeparSixto randomized clinical trial","volume":"32","author":"Llop-Guevara","year":"2021","journal-title":"Ann Oncol"},{"key":"key20260811124601_b20-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"100157","DOI":"10.1016\/j.esmorw.2025.100157","article-title":"Treatment toxicities and pathological response through the evolution of neoadjuvant regimens in early triple-negative breast cancer","volume":"9","author":"Arnaud","year":"2025","journal-title":"ESMO Real World Data Digit Oncol"},{"key":"key20260811124601_b21-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"100061","DOI":"10.1016\/j.esmorw.2024.100061","article-title":"Real-world safety and effectiveness of neoadjuvant chemotherapy combination with pembrolizumab in triple-negative breast cancer","volume":"5","author":"Rached","year":"2024","journal-title":"ESMO Real World Data Digit Oncol"},{"key":"key20260811124601_b22-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"104473","DOI":"10.1016\/j.breast.2025.104473","article-title":"Immune-related adverse events among patients with early-stage triple-negative breast cancer treated with pembrolizumab plus chemotherapy: Real-world data from the Neo-Real\/GBECAM 0123 study","volume":"83","author":"Andrade","year":"2025","journal-title":"Breast"},{"key":"key20260811124601_b23-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"e701","DOI":"10.1016\/j.clbc.2024.08.005","article-title":"Detrimental impact of chemotherapy dose reduction or discontinuation in early stage triple-negative breast cancer treated with pembrolizumab and neoadjuvant chemotherapy: A multicenter experience","volume":"24","author":"Krishnan","year":"2024","journal-title":"Clin Breast Cancer"},{"key":"key20260811124601_b24-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant capecitabine for breast cancer after preoperative chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"key":"key20260811124601_b25-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1056\/NEJMoa2105215","article-title":"Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer","volume":"384","author":"Tutt","year":"2021","journal-title":"N Engl J Med"},{"key":"key20260811124601_b26-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1016\/j.annonc.2022.09.159","article-title":"Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1\/2 and high-risk, early breast cancer","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann Oncol"},{"key":"key20260811124601_b27-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.ijrobp.2015.05.015","article-title":"Role of ultrasonography of regional nodal basins in staging triple-negative breast cancer and implications for local-regional treatment","volume":"93","author":"Shaitelman","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key20260811124601_b28-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"592","DOI":"10.4143\/crt.2022.998","article-title":"Impact of postmastectomy radiation therapy on breast cancer patients according to pathologic nodal status after modern neoadjuvant chemotherapy","volume":"55","author":"Kim","year":"2023","journal-title":"Cancer Res Treat"},{"key":"key20260811124601_b29-ol-32-3-15775","first-page":"6632635","article-title":"Impact of postmastectomy radiotherapy on locoregional control and disease-free survival in patients with breast cancer treated with neoadjuvant chemotherapy","volume":"2021","author":"Zhang","year":"2021","journal-title":"J Oncol"},{"key":"key20260811124601_b30-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.2147\/OTT.S158482","article-title":"Postmastectomy radiotherapy reduces locoregional and disease recurrence in patients with stage II\u2013III triple-negative breast cancer treated with neoadjuvant chemotherapy and mastectomy","volume":"11","author":"Chen","year":"2018","journal-title":"Onco Targets Ther"},{"key":"key20260811124601_b31-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa2414859","article-title":"Omitting regional nodal irradiation after response to neoadjuvant chemotherapy","volume":"392","author":"Mamounas","year":"2025","journal-title":"N Engl J Med"},{"key":"key20260811124601_b32-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"2880","DOI":"10.1002\/cncr.33604","article-title":"Early ultrasound evaluation identifies excellent responders to neoadjuvant systemic therapy among patients with triple-negative breast cancer","volume":"127","author":"Adrada","year":"2021","journal-title":"Cancer"},{"key":"key20260811124601_b33-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1200\/JCO-25-01023","article-title":"Addition of carboplatin to sequential taxane-anthracycline neoadjuvant chemotherapy in triple-negative breast cancer: A phase III randomized controlled trial","volume":"44","author":"Gupta","year":"2026","journal-title":"J Clin Oncol"},{"key":"key20260811124601_b34-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10549-023-07011-0","article-title":"Neoadjuvant carboplatin in triple-negative breast cancer: Results from NACATRINE, a randomized phase II clinical trial","volume":"202","author":"de P\u00e1dua Souza","year":"2023","journal-title":"Breast Cancer Res Treat"},{"key":"key20260811124601_b35-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1200\/JCO.2014.57.0572","article-title":"Impact of the addition of carboplatin and\/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)","volume":"33","author":"Sikov","year":"2015","journal-title":"J Clin Oncol"},{"key":"key20260811124601_b36-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1200\/JCO.21.01506","article-title":"CALGB 40603 (Alliance): Long-term outcomes and genomic correlates of response and survival after neoadjuvant chemotherapy with or without carboplatin and bevacizumab in triple-negative breast cancer","volume":"40","author":"Shepherd","year":"2022","journal-title":"J Clin Oncol"},{"key":"key20260811124601_b37-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"103712","DOI":"10.1016\/j.breast.2024.103712","article-title":"Platinum chemotherapy for early triple-negative breast cancer","volume":"75","author":"Mason","year":"2024","journal-title":"Breast"},{"key":"key20260811124601_b38-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.annonc.2022.01.009","article-title":"Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial","volume":"33","author":"Geyer","year":"2022","journal-title":"Ann Oncol"},{"key":"key20260811124601_b39-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1001\/jamaoncol.2023.5033","article-title":"Clinical and biomarker findings of neoadjuvant pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer: NeoPACT phase 2 clinical trial","volume":"10","author":"Sharma","year":"2024","journal-title":"JAMA Oncol"},{"key":"key20260811124601_b40-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/S1470-2045(24)00757-5","article-title":"Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902\/IBCSG 61\u201320; Neo-N): A non-comparative, open-label, randomized phase 2 trial","volume":"26","author":"Zdenkowski","year":"2025","journal-title":"Lancet Oncol"},{"key":"key20260811124601_b41-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"4995","DOI":"10.1158\/1078-0432.CCR-22-0482","article-title":"De-escalated neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Impact of molecular markers and final survival analysis of the WSG-ADAPT-TN trial","volume":"28","author":"Gluz","year":"2022","journal-title":"Clin Cancer Res"},{"key":"key20260811124601_b42-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.annonc.2023.11.018","article-title":"Response-guided neoadjuvant sacituzumab govitecan for localized triple-negative breast cancer: Results from the NeoSTAR trial","volume":"35","author":"Spring","year":"2024","journal-title":"Ann Oncol"},{"key":"key20260811124601_b43-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"17588359251316176","DOI":"10.1177\/17588359251316176","article-title":"TROPION-Breast04: A randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-na\u00efve early-stage triple negative or HR-low\/HER2-negative breast cancer","volume":"17","author":"McArthur","year":"2025","journal-title":"Ther Adv Med Oncol"},{"key":"key20260811124601_b44-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"17588359241248336","DOI":"10.1177\/17588359241248336","article-title":"TROPION-Breast03: A randomized phase III global trial of datopotamab deruxtecan \u00b1 durvalumab in patients with triple-negative breast cancer and residual invasive disease at surgical resection after neoadjuvant therapy","volume":"16","author":"Bardia","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"key20260811124601_b45-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41523-024-00676-w","article-title":"Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer","volume":"10","author":"Bonadio","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"key20260811124601_b46-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1158\/1078-0432.CCR-20-3646","article-title":"Randomized phase II trial of anthracycline-free and anthracycline-containing neoadjuvant carboplatin chemotherapy regimens in stage I\u2013III triple-negative breast cancer (NeoSTOP)","volume":"27","author":"Sharma","year":"2021","journal-title":"Clin Cancer Res"},{"key":"key20260811124601_b47-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1007\/s12672-025-03435-w","article-title":"Efficacy and safety of platinum-based, anthracycline-free neoadjuvant chemotherapy for triple-negative breast cancer: A systematic review and meta-analysis","volume":"16","author":"Du","year":"2025","journal-title":"Discov Oncol"},{"key":"key20260811124601_b48-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"102171","DOI":"10.1016\/j.tranon.2024.102171","article-title":"Comparative efficacy of anthracycline-free and anthracycline-containing neoadjuvant chemoimmunotherapy regimens for triple-negative breast cancer","volume":"51","author":"Wei","year":"2025","journal-title":"Transl Oncol"},{"key":"key20260811124601_b49-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1158\/1078-0432.CCR-25-0289","article-title":"Application of neoadjuvant docetaxel plus cisplatin in early-stage triple-negative breast cancer (HELEN-001): Results from a phase II trial","volume":"31","author":"Jiao","year":"2025","journal-title":"Clin Cancer Res"},{"key":"key20260811124601_b50-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1038\/s41586-024-07384-2","article-title":"The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer","volume":"629","author":"Abraham","year":"2024","journal-title":"Nature"},{"key":"key20260811124601_b51-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"2397","DOI":"10.1038\/s41591-025-03725-4","article-title":"Peri-operative atezolizumab in early-stage triple-negative breast cancer: Final results and ctDNA analyses from the randomized phase 3 IMpassion031 trial","volume":"31","author":"Mittendorf","year":"2025","journal-title":"Nat Med"},{"key":"key20260811124601_b52-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): A randomised, double-blind, phase 3 trial","volume":"396","author":"Mittendorf","year":"2020","journal-title":"Lancet"},{"key":"key20260811124601_b53-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.annonc.2022.02.004","article-title":"Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study","volume":"33","author":"Gianni","year":"2022","journal-title":"Ann Oncol"},{"key":"key20260811124601_b54-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"S1258","DOI":"10.1016\/j.annonc.2023.10.009","article-title":"LBA19 Event-free survival (EFS) analysis of neoadjuvant taxane\/carboplatin with or without atezolizumab followed by an adjuvant anthracycline regimen in high-risk triple negative breast cancer (TNBC): NeoTRIP Michelangelo randomized study","volume":"34","author":"Gianni","year":"2023","journal-title":"Ann Oncol"},{"key":"key20260811124601_b55-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1001\/jama.2024.23560","article-title":"Camrelizumab vs placebo in combination with chemotherapy as neoadjuvant treatment in patients with early or locally advanced triple-negative breast cancer: The camrelief randomized clinical trial","volume":"333","author":"Chen","year":"2025","journal-title":"JAMA"},{"key":"key20260811124601_b56-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1038\/s41591-024-03249-3","article-title":"Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: A phase 2 adaptive trial","volume":"30","author":"Nederlof","year":"2024","journal-title":"Nat Med"},{"key":"key20260811124601_b57-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"4680","DOI":"10.1158\/1078-0432.CCR-25-1288","article-title":"Atezolizumab monotherapy window preceding combined neoadjuvant chemo- and immune therapy in triple-negative breast cancer: the neoMono trial","volume":"31","author":"Kolberg","year":"2025","journal-title":"Clin Cancer Res"},{"key":"key20260811124601_b58-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"4900","DOI":"10.1158\/1078-0432.CCR-24-0149","article-title":"The Immune-related 27-gene signature DetermaIO predicts response to neoadjuvant atezolizumab plus chemotherapy in triple-negative breast cancer","volume":"30","author":"Dugo","year":"2024","journal-title":"Clin Cancer Res"},{"key":"key20260811124601_b59-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41523-025-00828-6","article-title":"Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer","volume":"11","author":"Balko","year":"2025","journal-title":"NPJ Breast Cancer"},{"key":"key20260811124601_b60-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1158\/1078-0432.CCR-21-3215","article-title":"Predictive markers of response to neoadjuvant durvalumab with nab-paclitaxel and dose-dense doxorubicin\/cyclophosphamide in basal-like triple-negative breast cancer","volume":"28","author":"Blenman","year":"2022","journal-title":"Clin Cancer Res"},{"key":"key20260811124601_b61-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"102459","DOI":"10.1016\/j.ctrv.2022.102459","article-title":"Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: What are the evidences?","volume":"110","author":"Bonadio","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"key20260811124601_b62-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ijrobp.2024.11.109","article-title":"Concurrent versus sequential adjuvant capecitabine-based chemoradiation in residual triple-negative breast cancer after preoperative systemic therapy: A multicenter comparative study","volume":"122","author":"Kim","year":"2025","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key20260811124601_b63-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1001\/jamaoncol.2022.5074","article-title":"Concurrent olaparib and radiotherapy in patients with triple-negative breast cancer: The phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer trial","volume":"8","author":"Loap","year":"2022","journal-title":"JAMA Oncol"},{"key":"key20260811124601_b64-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"1828","DOI":"10.1002\/ijc.33737","article-title":"Combination of Olaparib with radiotherapy for triple-negative breast cancers: One-year toxicity report of the RADIOPARP Phase I trial","volume":"149","author":"Loap","year":"2021","journal-title":"Int J Cancer"},{"key":"key20260811124601_b65-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s12672-025-03172-0","article-title":"Real world feasibility of combining pembrolizumab with radiotherapy in early triple negative breast cancer","volume":"16","author":"Colciago","year":"2025","journal-title":"Discov Oncol"},{"key":"key20260811124601_b66-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/COC.0000000000001236","article-title":"Real-world safety of concurrent pembrolizumab and radiotherapy in triple-negative breast cancer","volume":"49","author":"El Fakih","year":"2026","journal-title":"Am J Clin Oncol"},{"key":"key20260811124601_b67-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"5180","DOI":"10.1245\/s10434-024-15359-w","article-title":"Impact of neoadjuvant chemoimmunotherapy on surgical outcomes and time to radiation in triple-negative breast cancer","volume":"31","author":"Myers","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"key20260811124601_b68-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"531","DOI":"10.4143\/crt.2023.996","article-title":"Implication of pre- and post-radiotherapy ctDNA dynamics in patients with residual triple-negative breast cancer at surgery after neoadjuvant chemotherapy: Findings from a prospective observational study","volume":"56","author":"Lee","year":"2024","journal-title":"Cancer Res Treat"},{"key":"key20260811124601_b69-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.annonc.2022.11.005","article-title":"Results of the c-TRAK TN trial: A clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early stage triple negative breast cancer","volume":"34","author":"Turner","year":"2023","journal-title":"Ann Oncol"},{"key":"key20260811124601_b70-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13058-025-01986-y","article-title":"Role of circulating tumor DNA in early-stage triple-negative breast cancer: A systematic review and meta-analysis","volume":"27","author":"Zhang","year":"2025","journal-title":"Breast Cancer Res"},{"key":"key20260811124601_b71-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41523-023-00512-7","article-title":"ctDNA and residual cancer burden are prognostic in triple-negative breast cancer patients with residual disease","volume":"9","author":"Stecklein","year":"2023","journal-title":"NPJ Breast Cancer"},{"key":"key20260811124601_b72-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1001\/jamaoncol.2020.2295","article-title":"Association of circulating tumor DNA and circulating tumor cells after neoadjuvant chemotherapy with disease recurrence in patients with triple-negative breast cancer: Preplanned secondary analysis of the BRE12-158 Randomized clinical trial","volume":"6","author":"Radovich","year":"2020","journal-title":"JAMA Oncol"},{"key":"key20260811124601_b73-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"14704","DOI":"10.1038\/s41598-020-71236-y","article-title":"Prognostic and predictive value of circulating tumor DNA during neoadjuvant chemotherapy for triple negative breast cancer","volume":"10","author":"Cavallone","year":"2020","journal-title":"Sci Rep"},{"key":"key20260811124601_b74-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.annonc.2023.08.004","article-title":"Circulating tumor DNA association with residual cancer burden after neoadjuvant chemotherapy in triple-negative breast cancer in TBCRC 030","volume":"34","author":"Parsons","year":"2023","journal-title":"Ann Oncol"},{"key":"key20260811124601_b75-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41523-023-00607-1","article-title":"Circulating tumour mutation detection in triple-negative breast cancer as an adjunct to tissue response assessment","volume":"10","author":"Zaikova","year":"2024","journal-title":"NPJ Breast Cancer"},{"key":"key20260811124601_b76-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1158\/1078-0432.CCR-23-2326","article-title":"Comparison of circulating tumor DNA assays for molecular residual disease detection in early-stage triple negative breast cancer","volume":"30","author":"Coakley","year":"2024","journal-title":"Clin Cancer Res"},{"key":"key20260811124601_b77-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1158\/1078-0432.CCR-24-3145","article-title":"Detection of circulating tumor DNA using a tissue-free epigenomic assay is a highly prognostic biomarker in early-stage triple-negative breast cancer","volume":"31","author":"Ademuyiwa","year":"2025","journal-title":"Clin Cancer Res"},{"key":"key20260811124601_b78-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/bcr3670","article-title":"Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers","volume":"16","author":"Watkins","year":"2014","journal-title":"Breast Cancer Res"},{"key":"key20260811124601_b79-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1158\/1078-0432.CCR-24-3148","article-title":"RAD51 testing in patients with early HER2-Negative breast cancer and homologous recombination deficiency: A Post Hoc analysis of the GeparOLA trial","volume":"31","author":"Villacampa","year":"2025","journal-title":"Clin Cancer Res"},{"key":"key20260811124601_b80-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.ccell.2021.05.009","article-title":"Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II\/III breast cancer: Results from the adaptively randomized I-SPY2 trial","volume":"39","author":"Pusztai","year":"2021","journal-title":"Cancer Cell"},{"key":"key20260811124601_b81-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1158\/1078-0432.CCR-24-2806","article-title":"Neoadjuvant paclitaxel\/olaparib in comparison to paclitaxel\/carboplatin in patients with HER2-negative breast cancer and HRD - long-term survival of the GeparOLA study","volume":"31","author":"Fasching","year":"2025","journal-title":"Clin Cancer Res"},{"key":"key20260811124601_b82-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s13058-024-01883-w","article-title":"On-treatment biopsies to predict response to neoadjuvant chemotherapy for breast cancer","volume":"26","author":"Sinn","year":"2024","journal-title":"Breast Cancer Res"},{"key":"key20260811124601_b83-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13058-025-02070-1","article-title":"Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: An analysis of the I-SPY2 randomized clinical trial","volume":"27","author":"Leon-Ferre","year":"2025","journal-title":"Breast Cancer Res"},{"key":"key20260811124601_b84-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.annonc.2024.10.012","article-title":"TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapy","volume":"36","author":"Mart\u00edn","year":"2025","journal-title":"Ann Oncol"},{"key":"key20260811124601_b85-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41416-024-02917-y","article-title":"Heterogeneity of tertiary lymphoid structures predicts the response to neoadjuvant therapy and immune microenvironment characteristics in triple-negative breast cancer","volume":"132","author":"Wang","year":"2025","journal-title":"Br J Cancer"},{"key":"key20260811124601_b86-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1200\/JCO.2021.39.15_suppl.605","article-title":"Randomized phase III postoperative trial of platinum-based chemotherapy versus capecitabine in patients with residual triple-negative breast cancer following neoadjuvant chemotherapy: ECOG-ACRIN EA1131","volume":"39","author":"Mayer","year":"2021","journal-title":"J Clin Oncol"},{"key":"key20260811124601_b87-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"5467","DOI":"10.3390\/cancers14215467","article-title":"Post-neoadjuvant treatment strategies for patients with early breast cancer","volume":"14","author":"Agostinetto","year":"2022","journal-title":"Cancers (Basel)"},{"key":"key20260811124601_b88-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1080\/14796694.2024.2357534","article-title":"OptimICE-RD: Sacituzumab govitecan plus pembrolizumab versus pembrolizumab (\u00b1 capecitabine) for residual triple-negative breast cancer","volume":"20","author":"Tolaney","year":"2024","journal-title":"Future Oncol"},{"key":"key20260811124601_b89-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s10549-025-07814-3","article-title":"Survival impact of adjuvant capecitabine in triple-negative breast cancer Latin American patients with residual disease: A real-world study","volume":"214","author":"Graciano","year":"2025","journal-title":"Breast Cancer Res Treat"},{"key":"key20260811124601_b90-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1177\/1078155220971751","article-title":"The adjuvant use of capecitabine for residual disease following pre-operative chemotherapy for breast cancer: Challenges applying CREATE-X to a US population","volume":"27","author":"Beyerlin","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"key20260811124601_b91-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1158\/1078-0432.CCR-22-2191","article-title":"Triple-negative PAM50 non-basal breast cancer subtype predicts benefit from extended adjuvant capecitabine","volume":"29","author":"Asleh","year":"2023","journal-title":"Clin Cancer Res"},{"key":"key20260811124601_b92-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1038\/s41467-024-46961-x","article-title":"Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: The OXEL randomized phase II study","volume":"15","author":"Lynce","year":"2024","journal-title":"Nat Commun"},{"key":"key20260811124601_b93-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1186\/s12885-025-14673-0","article-title":"Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21)","volume":"25","author":"Lee","year":"2025","journal-title":"BMC Cancer"},{"key":"key20260811124601_b94-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"105804","DOI":"10.1016\/j.esmoop.2025.105804","article-title":"Genomic and transcriptomic analyses of residual invasive triple-negative breast cancer after neoadjuvant chemotherapy in the prospective MIRINAE trial (a randomized phase II trial of adjuvant atezolizumab plus capecitabine compared to capecitabine; KCSG-BR18-21)","volume":"10","author":"Im","year":"2025","journal-title":"ESMO Open"},{"key":"key20260811124601_b95-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1016\/j.annonc.2025.08.005","article-title":"A-BRAVE trial: A phase III randomized trial with anti-PD-L1 avelumab in high-risk triple-negative early breast cancer patients","volume":"36","author":"Conte","year":"2025","journal-title":"Ann Oncol"},{"key":"key20260811124601_b96-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1001\/jama.2024.26886","article-title":"Adjuvant atezolizumab for early triple-negative breast cancer: The ALEXANDRA\/IMpassion030 randomized clinical trial","volume":"333","author":"Ignatiadis","year":"2025","journal-title":"JAMA"},{"key":"key20260811124601_b97-ol-32-3-15775","article-title":"S1418\/BR006: A randomized phase III trial to evaluate efficacy and safety of MK-3475 (pembrolizumab) as adjuvant therapy for triple receptor-negative breast cancer with >\/=1 cm residual invasive cancer or positive lymph nodes (ypN1mi, ypN1-3) after neoadjuvant chemotherapy","author":"SWOG Cancer Research Network"},{"key":"key20260811124601_b98-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"key20260811124601_b99-ol-32-3-15775","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","article-title":"Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells","volume":"20","author":"Okajima","year":"2021","journal-title":"Mol Cancer Ther"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T09:46:08Z","timestamp":1786441568000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2026.15775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":99,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,7,21]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2026.15775","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]}}}